Intercell and Merck expand alliance to develop prophylactic vaccine and antibody treatments against Group A Streptococcus

30-Oct-2006

Intercell AG announced that it has extended its strategic partnership with Merck Sharp & Dohme Research Ltd., an affiliate of Merck & Co., Inc., to include development of a prophylactic vaccine against Group A Streptococcus infections.

The agreement is based on antigens that were discovered and validated by Intercell's proprietary bacterial Antigen Identification Program (AIP®). The agreement also includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by Group A Streptococcus.

Under the terms of the agreement, Intercell will provide to Merck certain Group A Streptococcusspecific antigens identified by its Antigen Identification Program (AIP®) that have promising profiles in preclinical vaccine models. Intercell will receive an upfront payment of USD 9.5 million and is eligible to receive milestone payments up to USD 76 million over the term of the agreement. Intercell will also receive royalties on future net sales of the product.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous